Research Topics
| Darren R FeldmanSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Late cardiovascular toxicity following chemotherapy for germ cell tumorsDarren R Feldman
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
J Natl Compr Canc Netw 10:537-44. 2012..In addition, recommendations are provided for the management of GCT survivors who received cisplatin-based chemotherapy and are therefore at risk for cardiovascular toxicity...
Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial designDarren R Feldman
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Cancer 118:981-6. 2012..The identification of novel active agents may be impaired by use of response as the primary endpoint in phase 2 trials. Improved endpoints could enhance the development of new effective agents...
TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysisDarren R Feldman
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Clin Oncol 28:1706-13. 2010..We now report the efficacy of TI-CE with prognostic factors for disease-free survival (DFS) and overall survival (OS) in our full data set of 107 patients...
Treatment of stage I seminoma: is it time to change your practice?Darren R Feldman
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, USA
J Hematol Oncol 1:22. 2008..Carboplatin is not yet a standard of care. Surveillance-based strategies, including risk-adapted policies that limit RT to patients with the greatest likelihood of relapse remain prudent at this time...
Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumorsDarren R Feldman
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
Invest New Drugs 28:523-8. 2010..Correlation between sunitinib treatment and tumor marker changes on the 50 mg 4/2 schedule suggest some pathways targeted by sunitinib (ie, angiogenesis) may be important to GCT biology...
Good-risk-advanced germ cell tumors: historical perspective and current standards of careDarren R Feldman
Genitourinary Oncology Service Division of Solid Tumors, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
World J Urol 27:463-70. 2009..The authors discuss the trials which led to the establishment of EPx4 and BEPx3 as today's treatment standards as well as the development of the IGCCCG prognostic model...
Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease siteTimothy A Masterson
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Urology 79:1079-84. 2012..To compare the survival outcomes of patients with advanced nonseminoma and extraretroperitoneal (ERP) disease observed for a clinical complete response (CCR) with those demonstrating a pathologic complete response (PCR)...
Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancerTimothy A Masterson
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Urology 79:156-9. 2012..We reviewed our institutional experience in patients undergoing resection of extraretroperitoneal (ERP) residual masses after chemotherapy to assess its impact on cancer progression and survival...
Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinomaAna M Molina
Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Cancer 118:1868-76. 2012..Everolimus, an oral mTOR inhibitor, and sunitinib, an oral tyrosine kinase inhibitor targeting VEGF, are standard agents in the management of metastatic RCC...
Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinomaAna M Molina
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Invest New Drugs 30:335-40. 2012..6 months for the 8 papillary patients (95% CI, 1.4-7.1). The robust objective responses sunitinib had produced in clear cell RCC could not be demonstrated in this study comprised of patients with non-clear cell histologies...
Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumorsAshwin Jathavedam
Infectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Biol Blood Marrow Transplant 14:595-600. 2008..In conclusion, serious morbidity from infection is uncommon among GCT patients receiving high-dose chemotherapy with ASCT. Isolation and aggressive antifungal and antiviral prophylaxis is not warranted in these patients...
Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced diseaseAna M Molina
Department of Medicine, Genitourinary Oncology Service, Weil Medical College of Cornell University, New York, NY, USA
Am J Clin Oncol 34:454-9. 2011..Sarcomatoid variant is a spindle cell phenotype of renal cell carcinoma (RCC), which is associated with a poor prognosis. We reviewed outcomes of systemic therapy for metastatic, sarcomatoid-variant RCC...
Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumorsDarren R Feldman
Genitourinary Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Invest New Drugs 25:487-90. 2007..For patients who had previously received taxane therapy, ixabepilone was not efficacious in the treatment of cisplatin-refractory GCT...
Outcomes after resection of postchemotherapy residual neck mass in patients with germ cell tumors--an updateAmit Gupta
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Urology 77:655-9. 2011..To examine histologic findings and clinical outcomes of patients who underwent neck dissection for residual neck masses...
Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinomaDarren R Feldman
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 27:1432-9. 2009..In this phase I study, the maximum-tolerated dose (MTD) and safety of sunitinib in combination with bevacizumab were examined in patients with advanced RCC...
Medical treatment of advanced testicular cancerDarren R Feldman
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
JAMA 299:672-84. 2008..Clinicians need to be familiar with the available treatment regimens for testicular cancer and their associated toxic effects...
A review of second-line chemotherapy and prognostic models for disseminated germ cell tumorsMartin H Voss
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Hematol Oncol Clin North Am 25:557-76, viii -ix. 2011..Clinical factors can help prognosticate patients, and recently an international effort developed a prognostic model for the second-line setting that can be universally applied in future studies...
Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumorsJames E Korkola
Cell Biology Program, Sloan Kettering Institute for Cancer Research, New York, USA
J Clin Oncol 27:5240-7. 2009..Currently, patients are risk-stratified on the basis of clinical presentation and serum tumor markers. The introduction of molecular markers could improve outcome prediction...
High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysisRussell A Moore
Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room H709, New York, NY 10065, USA
J Clin Oncol 29:3466-73. 2011....
Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinomaDarren R Feldman
Genitourinary Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Genitourin Cancer 6:25-30. 2008..In this study, the efficacy and toxicity of pegylated IFN was assessed in patients with metastatic renal cell carcinoma (mRCC)...
Contemporary lymph node counts during primary retroperitoneal lymph node dissectionR Houston Thompson
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Urology 77:368-72. 2011..We report our contemporary single-surgeon experience with lymph node counts during primary RPLND for nonseminomatous germ cell tumors...
Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitorsYevgeniy Balagula
Department of Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA
Cancer 118:5078-83. 2012..Inhibitors of mammalian target of rapamycin (mTOR), such as temsirolimus and everolimus, have been associated with a high rate of skin eruptions, but their clinical and histopathologic characteristics have not been explored...
High-dose chemotherapy and stem cell transplantation for advanced testicular cancerMartin H Voss
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10065, USA
Expert Rev Anticancer Ther 11:1091-103. 2011..Patients that relapse after HDCT are usually considered incurable, and additional therapy is provided with palliative intent...
Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibitionFrancesca Cavallo
Department of Biomedicine and Prevention, Section of Anatomy, University of Rome Tor Vergata, Rome, Italy
PLoS ONE 7:e51563. 2012....
The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysisYevgeniy Balagula
Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Rockefeller Outpatient Pavilion Suite 228, 160 East 53rd Street, New York, NY 10022, USA
Invest New Drugs 30:1773-81. 2012..1-6.2, p < 0.001). Despite sharing the same spectrum of target receptors with sorafenib and sunitinib, pazopanib is associated with an unexpectedly low risk of HFSR. Further investigations are needed to elucidate HFSR pathogenesis...
Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumorsDana Rathkopf
Genitourinary Oncology Service, Department of Medicine, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Clin Cancer Res 15:7405-11. 2009..Preclinical data indicate that flavopiridol enhances oxaliplatin- and fluorouracil (5FU)-induced apoptosis in a sequence-dependent manner...
Novel targets and therapies for metastatic renal cell carcinomaDarren R Feldman
Division of Medical Oncology and Hematology, Department of Internal Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Oncology (Williston Park) 20:1745-53; discussion 1756. 2006..The ways in which these novel drugs are changing the standard of care for metastatic RCC and the future directions of RCC clinical trials are also discussed...
